A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy

Table 1 Major series on IPHC and/or EPIC after cytoreductive surgery for PMP, DMPM, and CRPC

Chief investigator	Year	Treatment center	Type	n	Intraperitoneal chemotherapy	Survival (%)
						3-yr	5-yr
Piso et al[1]	2001	Hanover, Germany	PMP	17	IPHC: cisplatin	75	-
Butterworth et al[2]	2002	Vancouver, Canada	PMP	11	EPIC: 5-FU + mitomycin	60	-
Witkamp et al[3]	2001	Amsterdam, Netherlands	PMP	46	IPHC: mitomycin	81	-
Sugarbaker et al[4]	2001	Washington, USA	PMP	501	EPIC: 5-FU + mitomycin	-	80
					IPHC: mitomycin
Loggie et al[5]	2001	Winston-Salem, USA	DMPM	12	IPHC: mitomycin	50	-
Sebbag et al[6]	2000	Washington, USA	DMPM	33	IPHC: cisplatin + doxorubicin	56	47
Sugarbaker et al[7]	2003	Washington, USA	DMPM	68	IPHC: cisplatin + doxorubicin	60	50
					EPIC: paclitaxel
Feldman et al[8]	2003	Bethesda, USA	DMPM	49	IPHC: cisplatin ± paclitaxel	-	59
Fujimura et al[9]	1999	Kanazawa, Japan	CRPC	14	IPHC: cisplatin + mitomycin + etoposide	21	-
Witkamp et al[10]	2001	Amsterdam, Netherlands	CRPC	29	IPHC: mitomycin	23	-
Elias et al[11]	2001	Villejuif, France	CRPC	64	IPHC: mitomycin ± cisplatin	47	27
					EPIC: mitomycin + 5-FU
Pestieau et al[12]	2000	Washington, USA	CRPC	104	IPHC: mitomycin	45	30
					EPIC: 5-FU
Zoetmulder et al[13]	2002	Amsterdam, Netherlands	CRPC	94	IPHC: mitomycin	-	30
Shen et al[14]	2004	Winston-Salem, USA	CRPC	77	IPHC: mitomycin	25	17
Glehen et al[15]	2004	Multi-institutions	CRPC	506	IPHC or EPIC	-	-

IPHC: Intraperitoneal hyperthermic chemotherapy; EPIC: Early postoperative intraperitoneal chemotherapy; PMP: Pseudo-myxoma peritonei; DMPM: Diffuse malignant peritoneal mesothelioma; CRPC: Colo-rectal peritoneal carcinomatosis.